Human Trials

Parkinson’s disease study reveals how cancer drug reduces toxic protein in brain

Researchers at the US-based Georgetown University Medical Center claimed to have understood how a cancer drug functions in the brains of patients with Parkinson’s disease.

Lilly’s CYRAMZA meets primary endpoint in phase 3 RELAY trial

Eli Lilly and Company has announced that its Phase 3 RELAY study of CYRAMZA (ramucirumab) met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant improvement in the time patients lived without their cancer growing or spreading after starting treatment.

Tenax Therapeutics recruits first patient in phase 2 pulmonary hypertension clinical trial

Tenax Therapeutics announced that the first patient has been randomized for its phase 2 trial designed to evaluate levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF).

Gilead announces data from two studies supporting further development of investigational HIV-1 capsid inhibitor GS-6207

Gilead Sciences has announced findings from two studies that support the further development of GS-6207, a novel, selective, first-in-class inhibitor of HIV-1 capsid function, for potential future use as part of long-acting HIV combination therapy.

ViiV Healthcare reports positive data for two phase 3 HIV trials of cabotegravir, rilpivirine regimen

ViiV Healthcare presented comprehensive 48-week data from the ATLAS (Antiretroviral Therapy as Long-Acting Suppression) and FLAIR (First Long-Acting Injectable Regimen) pivotal phase III studies of the novel, investigational, long-acting regimen of cabotegravir and rilpivirine.

HIV remission achieved in second patient

A second person has experienced sustained remission from HIV-1 after ceasing treatment, reports a paper led by UCL and Imperial College London.

Novo Nordisk’s Ozempic meets primary endpoint in Sustain 9 diabetes trial

Novo Nordisk’s Ozempic (semaglutide), in combination to SGLT-2 inhibitor (SGLT-2i) therapy, met the primary endpoint in a phase 3 trial in patients with type 2 diabetes.

Novartis data confirm rapid response and high efficacy of Cosentyx in psoriasis patients for first time in China

Novartis announced new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosentyx (secukinumab).

Verona’s ensifentrine DPI formulation succeeds in part 1 of COPD trial

Verona Pharma said that the first part of a two-part phase 2 trial of ensifentrine in a dry powder inhaler (DPI) formulation for the treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD) has yielded positive interim efficacy and safety data.